amyloid polyneuropathy sentence in Hindi

Examples

1. Tafamidis is one such small molecule that has been approved by several international regulatory agencies for the treatment of Transthyretin Familial Amyloid Polyneuropathy.
2. The donated liver has a disorder known as familial amyloid polyneuropathy, or FAP, which causes it to produce proteins that collect in the body and cause other dysfunctions.
3. The donated liver has a disorder known as familial amyloid polyneuropathy, or FAP, which causes it to produce proteins that collect in the body and cause other disfunctions.
4. It is currently being considered for approval by the United States Food and Drug Administration ( FDA ) for the treatment of early stage transthyretin-related hereditary amyloidosis or familial amyloid polyneuropathy or FAP.
5. In September 2013 Tafamidis was approved for use in Japan by the Pharmaceuticals and Medical Devices Agency, specifically for the treatment of transthyretin-related hereditary amyloidosis or familial amyloid polyneuropathy or FAP ( all mutations ).
6. Tafamidis was approved for use in the European Union by the European Medicines Agency in November 2011, specifically for the treatment of early stage transthyretin-related hereditary amyloidosis or familial amyloid polyneuropathy or FAP ( all mutations ).
7. This drug, now called Tafamidis or Vyndaqel, slowed the progression of familial amyloid polyneuropathy in an 18-month placebo controlled trial and in a 12-month extension study sponsored by FoldRx Pharmaceuticals ( acquired by Pfizer in 2010 ) . was approved for the treatment of Familial amyloid Polyneuropathy by the European Medicines Agency in late 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in 2013.
8. This drug, now called Tafamidis or Vyndaqel, slowed the progression of familial amyloid polyneuropathy in an 18-month placebo controlled trial and in a 12-month extension study sponsored by FoldRx Pharmaceuticals ( acquired by Pfizer in 2010 ) . was approved for the treatment of Familial amyloid Polyneuropathy by the European Medicines Agency in late 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in 2013.